Exploring the Neurobiology of Cognitive Dysfunction in Down Syndrome William Mobley M.D., Ph.D. and Craig Garner Ph.D. Stanford University Center for Research.

Slides:



Advertisements
Similar presentations
Johns Hopkins Medicine Strategic Plan
Advertisements

Long Term effects of drugs on the brain
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Long-term Potentiation as a Physiological Phenomenon
NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.
Optical controlling reveals time- dependent roles for adult-born dentate granule cells Yan Gu, Maithe Arruda-Carvalho, Jia Wang, Stephen R Janoschka, Sheena.
CDC Resources and Tools for Aging Services Professionals Angela Johnson Deokar, MPH, CHES, CPH Public Health Advisor, Healthy Aging Program Centers for.
Lenka Beránková Department of Health Promotion.  chronic neurological condition characterized by temporary changes in the electrical function of the.
Validity with Pragmatism Specific Issues in experimental design and implementation II-A.
MCB 135K: Discussion March 2, General Info Mid-Term I: –Avg 87 –Std. Deviation 10 –Re-grades by next Wednesday Include a cover sheet that addresses.
No Theory of Mind. Weak Central Coherence Executive Dysfunction.
The Accelerated Cure Project for MS 1 Suffolk University November 7 th, 2011 Robert N. McBurney, Chief Executive Officer A New Model to Speed the Pace.
The Influence of Transportation and Access on the Well-Being of Older Adults William A. Satariano, Ph.D., MPH School of Public Health University of California,
NEUROSCIENCE INSTITUTE AT STANFORD (NIS) September 27, 2004.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
ALZHEIMER’S AND DOWN’S SYNDROME
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
The NIH Roadmap for Medical Research
Purpose: Serves as guide to accelerate research to reduce the prevalence and burden of obesity, so that people can look forward to healthier lives Enhances.
Gene Therapy in Huntington’s Disease Project was done by Rejan Chin & Sharisa Ford.
Copyright © 2007 Wolters Kluwer Health | Lippincott Williams & Wilkins Neuroscience: Exploring the Brain, 3e Chapter 25: Molecular Mechanisms of Learning.
CLINICAL & TRANSLATIONAL SCIENCE AWARDS CLINICAL & TRANSLATIONAL SCIENCE AWARDS Transforming Biomedical Research To Improve the Health of Our Nation’s.
AMPAKINE Compounds for the Treatment of Rett Syndrome
Lis Nielsen, Ph.D. Division of Behavioral and Social Research (BSR) National Institute on Aging NIA/IPSR Workshop: Advancing Integrative.
Questions 17-1 Q: What happens to a nerve impulse once it reaches the end of an axon? Q: How does one neuron communicate with another?
Mind and Brain Presented by: Sarah C. Bradshaw. Contributing Sciences “The fields of neuroscience and cognitive science are helping to satisfy this fundamental.
CHAPTER TWO CHAPTER TWO Neuroscience as a Basis for Adult Development and Aging.
Alzheimer’s By : Dylan Smith. Alzheimer's Disease Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer's, is the most common form of Dementia.
Improving emotional face perception in ASD with bumetamide: behavioral and fMRI data Nouchine Hadjikhani, MD, PhD Martinos Center for Biomedical Imaging.
THE NEW APPROACH. Introduction For a long period of time it was state of the art to design drugs displaying one defined pharmacological mode of action.
Amnesia Syndromes Lesson 22. Wernicke-Korsakoff’s Syndrome n Deficits similar to H.M. l Anterograde l retrograde more severe n Cause: Long-term alcohol.
Socio-behavioral Issues in Aging and HIV: Critical for Success in Prevention and Care Sherry Deren Center for Drug Use and HIV Research, NYU College of.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Delirium and Dementia.
Changju Lee Visual System Neural Network Lab. Department of Bio and Brain Engineering.
FMRI guided Microarray analysis Imaging-Guided Microarray: Isolating Molecular Profiles That Dissociate Alzheimer’s Disease from Normal Aging  A.C. Pereira,
Pittsburgh Fly Meeting, July 29, 2011
1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.
Progressive, degenerative disorder Attacks the brain's neurons Results in loss of memory, thinking and language skills, and behavioral changes Confusion.
Control of Attention in schizophrenia 1.Advance understanding of schizophrenia. Move from description of deficits to explanation of specific mechanisms.
Mechanisms for memory: Introduction to LTP Bailey Lorv Psych 3FA3 November 15, 2010.
Plasticity and Promise: A New Era in Brain Research and Psychiatry
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
Physiological Explanations for Changes in the Brain with Age.
Stratifying RTT Patients for Clinical Trials A Mutation Based Approach
 also known as human kinetics  scientific study of human movement  addresses physiological, mechanical, and psychological mechanisms Kinesiology means.
LONG-TERM POTENTIATION (LTP) Introduction LTP as a candidate mechanism for the activity-dependent change in the strength of synaptic connections LTP is.
Slide 1 Neuroscience: Exploring the Brain, 3rd Ed, Bear, Connors, and Paradiso Copyright © 2007 Lippincott Williams & Wilkins Bear: Neuroscience: Exploring.
Research How-To’s in a Community Setting Gregory W. Heath, DHSc, MPH Director of Research.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Pharmacology of central Neurotransmitters Prof. Yieldez.
Neurotransmissions in the Central Nervous System Prof. Alhaider.
The NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research February 20, 2014 Jill Heemskerk, PhD Deputy Director, Division.
Personnel Director Curt R. Freed, M.D. Professor of Medicine and Pharmacology Professor of Medicine and Pharmacology Head, Div CP and Tox Head, Div CP.
Cognitive Impairment and Neural Pregenitor Cell Destruction (on Lister hooded rats) as a Result of Chemotherapy Morgan Earle, Department of Biological.
Section 7.4 Effects of Aging. Introduction 1. The nervous system is formed during the first month of embryonic development 2. Any maternal infection can.
Camara M1, Anscomb H.L. 2 and Baune B.T. 1,2
Contributions of BDNF to the Maturation of Cortical Inhibitory Circuits Ali Hamodi.
Capacity of auto-associative networks
Amnesia Syndromes Lecture 21.
Volume 51, Issue 1, Pages (July 2006)
Chapter 30 Delirium and Dementia
P. Alexander Arguello, Joseph A. Gogos  Trends in Neurosciences 
Gene Therapy Learning Goal: To explore gene therapy. Success Criteria:
Gene Therapy Section 6.5.
Sacha B. Nelson, Vera Valakh  Neuron 
Alzheimer’s Disease Neurobiology
Scientific Background
CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease  Fang Huang, Minghui Wang, Rong Liu, Jian-Zhi Wang, Eric Schadt, Vahram.
Neuroscience: Exploring the Brain, 3e
Presentation transcript:

Exploring the Neurobiology of Cognitive Dysfunction in Down Syndrome William Mobley M.D., Ph.D. and Craig Garner Ph.D. Stanford University Center for Research and Treatment of Down Syndrome

The Center for Research and Treatment of Down Syndrome Helping People with Down Syndrome Live More Independent Lives

Defining the Problem Neurological manifestations of Down syndrome are disabling. Cognitive problems are significant -extend across the lifespan -development is globally slowed -marked involvement of memory, speech and language All people with Down syndrome show the neuropathology of Alzheimer’s disease by the age of 40 and many show further cognitive decline.

Creating a research community that listens to parents and to people with Down syndrome. Building a research enterprise that brings the best scientists and clinicians to work on the problem and that uses the most modern technologies. Defining research priorities on the basis of what will lead to effective treatments. Funding this work while insisting that researchers share data and credit. Rapidly moving new discoveries to new treatments. The Center for Research and Treatment of Down Syndrome

Small Change in Cognitive Capability could have Profound impact on Independence % Population Independent LivingDependent Living 15%

Attack from several directions 15% Cognitive Improvement Sleep CBT Brain

Down Syndrome – Important Facts Advances in Down syndrome have not kept pace with those in other fields -Too complex to understand -Too difficult to study -Too late to be of help

Federal research dollars per patient Alzheimer’sAutismDown Syndrome ALS Down Syndrome – Important Facts The Investment in Research is Tiny in Comparison to other Disorders

Neurons Cognition Neuronal systems Genes Development Clinical trials Industry Delivery Health Care Neuroscience Translating Research Advances in DS NIH Doesn’t Push: Industry Doesn’t Pull

Down Syndrome – The Conclusions People with Down syndrome have not been adequately served by the many advances that are revolutionizing our ability to understand and treat disorders of the nervous system. Without a fundamental change in research funding, and the culture in which it is carried out, there will be little progress in helping people with Down syndrome.

Neurons Cognition Neuronal systems Genes Development Clinical trials Industry Delivery Health Care Science Translating Research Advances in the Center for Down Syndrome Breaking Down Barriers Through Integration of Efforts

Stanford University Director: William Mobley Co-Director: Craig Garner Principle Investigators: Robert Malenka, Craig Garner, Irving Weissman, Barbara Sommer, Allan Reiss, Dan Madison, Emmanuel Mignot, William Mobley Associate Investigators: Pavel Belichenko, Alexander Kleschevnikov, Jean Delcroix, Ahmad Salehi, Subha Basu, Ke Zhan, Chengbiao Wu, Damien Colas, Fabian Fernandez, Martina Blank

DS Center Participants UCSF Charles Epstein Angela Villar UC Berkeley Lucia Jacobs Case Western Bruce Lamb Med Univ SC Kumar Sambamurti NYU Randy Nixon Johns Hopkins Roger Reeves UT Southwestern Luis Parada UCSD Eliezer Masliah Larry Goldstein Gorazd Stokin Harvard Weiming Xia

UNDERSTANDING AND TREATING DOWN SYNDROME -NOT TOO COMPLEX Because specific genes and mechanisms will be found to cause cognitive problems -NOT TOO DIFFICULT Because tools are available to find these genes and understand how an extra copy causes cognitive problems -NOT TOO LATE Because brain function can be modified, even in adults

Research Strategy Define the Abnormality of Interest in Down Syndrome Build the Model System to Recreate the Abnormality Find and Characterize the Abnormality in the Model Define the Gene(s) Pursue Treatments that Reduce the Expression of the Gene(s) or that Block the Mechanism Define the Mechanism

presynapse postsynapse

NEURONAL CIRCUITS ARE DISRUPTED IN DS x x DISRUPTED X X

A) Normal neonatal brain B) Down syndrome (DS; trisomy 21) (from Marin-Padilla, 1976). Synapse Structure is Abnormal in Individuals with Down Syndrome 10  m AB

Hypothesis That cognitive dysfunction in Down syndrome is due to abnormalities in the structure, function and maintenance of synapses and that each such abnormality is caused by the presence of an extra copy of a gene(s) on chromosome 21.

APP Grik1 Sod1 Gart Sim2 Dryk1a Ets2 Mx1 Sod1 Gart Sim2 Dryk1a Mx1 Ets2 APP Grik1 Sod1 Ts65DnTs1CjeMs1Ts65 A Mouse Model of Down Syndrome Gabpa These Mice Carry an Extra Copy of Many of the Genes Responsible For Down Syndrome

PP Sch MF CA1 A lv CA3 Entorhinal Cortex Anatomy of Circuits in the Hippocampus: a Brain Region Critical for Learning and Memory Dentate Gyrus Cholinergic Neuron DGC Perforant Path

Mossy cell GABAergic neuron GABAergic neuron GL IML OML MML Cholinergic neuron DGC PP

Synaptic Structure and Function are Abnormal in Ts65Dn Mice Synaptic Structure and Function are Abnormal in Ts65Dn Mice 2N mice Glu GAB A ACh Ts65Dn mice ACh Glu GABA

Enlarged Synapses: Possible Causes Suppression of normal excitatory input leads to increased size of synapses. -what gene(s) are involved? -what mechanism(s) is responsible? -affecting developing neurons, mature neurons, or both?

Synaptic Structure and Function are Abnormal in Ts65Dn Mice Synaptic Structure and Function are Abnormal in Ts65Dn Mice 2N mice Glu GAB A ACh Ts65Dn mice ACh Glu GABA

Dentate Gyrus CA3 CA1 MF PP Inhibitory neuron Synaptic Plasticity Was Suppressed in Ts65Dn Mice Synaptic Plasticity was Restored by Blocking Inhibition Synapses Become More Efficient During Learning – Synaptic Plasticity Abnormal Synaptic Function in Ts65Dn Mice

Proposed Mechanism for Decreased Synaptic Plasticity in Ts65Dn Increased inhibition Suppression of Learning Decreased Synaptic Plasticity

Research Strategy Define the Abnormality of Interest in Down Syndrome Build the Model System to Recreate the Abnormality Find and Characterize the Abnormality in the Model Define the Gene(s) Pursue Treatments that Reduce the Expression of the Gene(s) or that Block the Mechanism Define the Mechanism

Mossy cell GABA-ergic cell GABA-ergic cell GL IML PP OML MML Cholinergic neuron DGC

NTF

NEURONAL CIRCUITS ARE DISRUPTED IN DS x x DISRUPTED X X NTF

NGF Produced in Hippocampus Regulates the Differentiation, Survival and Maintenance of Cholinergic Neurons Hippocampus NGF Cholinergic Neuron These Cholinergic Neurons Degenerate In Alzheimer’s Disease and Down Syndrome

2NTs65Dn Amount of NGF Transported 125 I-NGF Cholinergic Neurons Hippocampus Reduced Axonal Transport of NGF from the Hippocampus to Cholinergic Neurons in Ts65Dn

Candidate Genes for Failed NGF Retrograde Transport GABPA App ADAMTS1 ADAMTS5 PRED28 ZNF294 C21orf6 USP16 CCT8 GRIK1 CLDN17 CLDN8 TIAM1 SOD1 T APP Grik1 Sod1 Gart Sim2 Dryk1a Ets2 Mx1 Ts65Dn Gabpa

Ts65Dn: APP+/+/+ Ts65Dn: APP+/+/- 2N Percent Cell profile area (  m 2 ) NGF Transport (percent of 2N) * ** 2N Ts65Dn/APP++- Ts65Dn/APP+++ Ts65Dn/APP++- Ts65Dn/APP+++ Deleting One Copy of App in Ts65Dn Mice Markedly Enhances 125 I-NGF Transport and Prevents BFCN Atrophy

Research Strategy Define the Abnormality of Interest in Down Syndrome Build the Model System to Recreate the Abnormality Find and Characterize the Abnormality in the Model Define the Gene(s) Pursue Treatments that Reduce the Expression of the Gene(s) or that Block the Mechanism Define the Mechanism

A Proposal for Pathogenesis Increased APP Gene Expression Cholinergic Neuron Dysfunction and Degeneration Decreased NGF Transport

A Proposal for Pathogenesis Increased APP Gene Expression No Cholinergic Neuron Dysfunction and Degeneration Normal NGF Transport Treatment

Summary 1)Synapses are abnormal in mouse models of Down syndrome. 2)Considerable progress is anticipated with respect to defining the genes and mechanisms responsible. 3)Current studies will lead to attempts to correct defects in mice. 4)Because the changes detected in mice are relevant to those in people with Down syndrome, this work should guide and hasten the development of new treatments – and this is our ultimate goal.